A groundbreaking initiative, titled Biomarker Research Integrating Data of Glyco-Immune Signatures and Clinical Evidence in Breast Cancer, is set to revolutionize the way aggressive breast cancer is detected and treated. This project focuses on uncovering biological indicators that can provide insights into the behavior of the disease in individual patients.
These indicators, known as biomarkers, are measurable biological signals found in blood, tissues, or other samples. They play a crucial role in helping healthcare professionals track the progression of cancer and make informed treatment choices. For instance, specific biomarkers can indicate whether a tumor is likely to grow rapidly or respond to certain therapies.
Understanding Tumor and Immune System Interactions
The research initiative unites experts from the Instituto de Tecnologia Química e Biológica António Xavier at NOVA University of Lisbon (ITQB NOVA) and the Portuguese Institute of Oncology (IPOFG). Their primary focus is on the interactions between cancer cells and their surrounding environment, commonly known as the tumor microenvironment.
This microenvironment comprises not only cancer cells but also adjacent immune cells, blood vessels, and other supportive structures. The research team is particularly interested in small molecules present on cell surfaces within this environment, as they may significantly contribute to the ability of tumors to evade detection by the immune system, thereby allowing unchecked cancer growth.
Decoding Tumor Communication with Immune Cells
"We have previously discovered how tumors communicate with specific immune cells to shield themselves," states Catarina Brito, head of the Advanced Cell Models laboratory at ITQB NOVA. "With the BRIDGE project, we aim to validate these findings using actual patient samples and translate this knowledge into clinical applications."
The IPOFG will provide patient samples to verify whether these laboratory findings are applicable in real-world clinical situations, a vital step in transforming scientific discoveries into practical medical tools.
"By identifying new biomarkers, we aspire to enhance the precision of therapies," Brito concludes.
Advancing Toward Personalized Breast Cancer Treatment
By deepening the understanding of how tumors evade immune responses, researchers are paving the way for new diagnostic and treatment strategies for breast cancer. This includes the identification of biomarkers that can be utilized to monitor the disease and the development of new therapeutic targets that promise more effective treatments.
The ultimate objective is to progress toward more personalized care, tailoring treatments to the unique characteristics of each patient's cancer rather than employing a uniform approach.
Funding and Future Prospects
The BRIDGE project is backed by the iNOVA4Health Lighthouse Projects (LHP) 2025 program, which supports research with significant potential for clinical application. By fostering collaboration among scientists, clinicians, and technology experts, the initiative aims to accelerate advancements in tackling major health challenges.
Over the next two years, the project is set to receive up to €75,000 to facilitate its efforts, with researchers optimistic that this funding will expedite the development of innovative strategies for understanding, monitoring, and treating some of the most aggressive types of breast cancer.